特 集
悪性リンパ腫；
びまん性大細胞型 B 細胞性リンパ腫克服の歴史
2022 年 81 巻 2 号 p. 83-86
詳細
2022 年 81 巻 2 号 p. 83-86
Surgical resection is not the treatment of choice for many blood neoplasms, such as malignant lymphoma. Thus,malignant lymphoma was one of the first diseases to which anticancer drug therapy was applied. In this specialissue entitled “Cancer Therapy,” we discuss the treatment of diffuse large B-cell lymphoma (DLBCL), which isthe most common form of malignant lymphoma. DLBCL has been widely treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy as the standard of care for approximately20 years. Furthermore, since the establishment of CHOP therapy in the 1970s, the primary treatment regimen forDLBCL has not changed for almost half a century. However, novel drugs with different mechanisms of action,such as polatuzumab vedotin and chimeric antigen receptor T cells, have been introduced in the past few years toimprove therapeutic outcomes. This article outlines the history of curative treatments for DLBCL, from establishing CHOP to the latest treatments.
